Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials

BACKGROUND: Neurofilament light chain (NfL), a neuronal cytoskeletal protein that is released upon neuroaxonal injury, is associated with multiple sclerosis (MS) relapsing activity and has demonstrated some prognostic ability for future relapse-related disease progression, yet its value in assessing...

Descripción completa

Detalles Bibliográficos
Autores principales: Bar-Or, Amit, Thanei, Gian-Andrea, Harp, Christopher, Bernasconi, Corrado, Bonati, Ulrike, Cross, Anne H., Fischer, Saloumeh, Gaetano, Laura, Hauser, Stephen L., Hendricks, Robert, Kappos, Ludwig, Kuhle, Jens, Leppert, David, Model, Fabian, Sauter, Annette, Koendgen, Harold, Jia, Xiaoming, Herman, Ann E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320523/
https://www.ncbi.nlm.nih.gov/pubmed/37354600
http://dx.doi.org/10.1016/j.ebiom.2023.104662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320523/
https://www.ncbi.nlm.nih.gov/pubmed/37354600
http://dx.doi.org/10.1016/j.ebiom.2023.104662

Ejemplares similares